MiRXES Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 300

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Latest Deal Amount
  • $150M

  • Investors
  • 13

MiRXES General Information

Description

Developer of a diagnostic test platform designed to detect cancer at an asymptomatic stage. The company specializes in providing clinical diagnostic tools that seek to recognize early cancer detection in clinical examinations with its microRNA quantification test, enabling healthcare professionals to identify cancer at early stages.

Contact Information

Website
www.mirxes.com
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • 2 Tukang Innovation Grove
  • Number 09-02 JTC MedTech Hub
  • Singapore, 618305
  • Singapore
+65 6816 0000
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2 Tukang Innovation Grove
  • Number 09-02 JTC MedTech Hub
  • Singapore, 618305
  • Singapore
+65 6816 0000

MiRXES Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MiRXES Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. IPO 25-Jul-2023 $150M 00000 Announced Generating Revenue/Not Profitable
6. Later Stage VC (Series D) 26-Jul-2023 0000 00000 Completed Product Development
5. Secondary Transaction - Private 00000 Completed Product Development
4. Later Stage VC (Series C) 08-Jul-2021 0000 00000 Completed Product Development
3. Early Stage VC (Series A) 11-Jul-2018 0000 000.00 00000 Completed Product Development
2. Grant 09-Mar-2016 $250.00 $2.84M Completed Product Development
1. Early Stage VC 01-Jan-2016 $2.84M $2.84M Completed Product Development
To view MiRXES’s complete valuation and funding history, request access »

MiRXES Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a diagnostic test platform designed to detect cancer at an asymptomatic stage. The company specializes in p
Diagnostic Equipment
Singapore, Singapore
300 As of 2024
00000
00000000 00000

000000

lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut l
0000000000 000000000
Beverly, MA
00 As of 0000
00.00
00000 00000

000000

sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat no
0000000000 000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MiRXES Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genomic Expression Venture Capital-Backed Beverly, MA 00 00.00 00000 00000
Veracyte Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
Intellia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
You’re viewing 5 of 9 competitors. Get the full list »

MiRXES Executive Team (12)

Name Title Board Seat
Lihan Zhou Ph.D Co-founder, Chief Executive Officer & Executive Director
Yvonne Wu Chief Executive Officer
Beng Lor Choo Chief Financial Officer
Zou Ruiyang Ph.D Co-Founder, Chief Technology Officer & Board Member
Martin Law Chief Investor Relations Officer & Managing Director, Hong Kong
You’re viewing 5 of 12 executive team members. Get the full list »

MiRXES Board Members (2)

Name Representing Role Since
Da Liu China Resources Capital Management Board Member 000 0000
Isaac Ho MiRXES Chief Investment Officer & Board Member 000 0000
To view MiRXES’s complete board members history, request access »

MiRXES Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MiRXES Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agency for Science, Technology and Research Government Minority 000 0000 000000 0
Beijing Fupu Corporation Minority 000 0000 000000 0
EDB Investments Corporation Minority 000 0000 000000 0
Mitsui & Company Corporation Minority 000 0000 000000 0
NHH Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

MiRXES Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Med247 31-Mar-2022 00000 0000 00.00 Clinics/Outpatient Services
Ark (Diagnostic Equipment) 01-Jan-2018 Joint Venture Diagnostic Equipment 000 00000
To view MiRXES’s complete investments history, request access »

Ready to get started?

Request a free trial

MiRXES Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Ark (Diagnostic Equipment) 01-Jan-2018 00000 000000 Completed
  • 2 buyers
To view MiRXES’s complete exits history, request access »

MiRXES FAQs

  • When was MiRXES founded?

    MiRXES was founded in 2014.

  • Who is the founder of MiRXES?

    Lihan Zhou Ph.D, Zou Ruiyang Ph.D, Heng-Phon Too Ph.D, and Sarah Ho are the founders of MiRXES.

  • Who is the CEO of MiRXES?

    Lihan Zhou Ph.D and Yvonne Wu are the CEOs of MiRXES.

  • Where is MiRXES headquartered?

    MiRXES is headquartered in Singapore, Singapore.

  • What is the size of MiRXES?

    MiRXES has 300 total employees.

  • What industry is MiRXES in?

    MiRXES’s primary industry is Diagnostic Equipment.

  • Is MiRXES a private or public company?

    MiRXES is a Private company.

  • What is MiRXES’s current revenue?

    The current revenue for MiRXES is 00000.

  • How much funding has MiRXES raised over time?

    MiRXES has raised $180M.

  • Who are MiRXES’s investors?

    Agency for Science, Technology and Research, Beijing Fupu, EDB Investments, Mitsui & Company, and NHH Ventures are 5 of 13 investors who have invested in MiRXES.

  • Who are MiRXES’s competitors?

    Genomic Expression, Veracyte, Voyager Therapeutics, Intellia Therapeutics, and CRISPR Therapeutics are some of the 9 competitors of MiRXES.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »